The death of an 18-year-old girl forces a change in the recommendations of AstraZeneca in Italy

“The possibility of using AstraZeneca for everyone in a discretionary way is not an invention of the regions or of some doctor: it is a suggestion that comes from the highest technical and scientific organisms to increase vaccination, and thus avoid more deaths.

Based on this, the President of Liguria, Giovanni Toti, has invited not to make firewood from the fallen tree after the death of an 18-year-old girl, Camilla Canepa, after inoculation of a dose of the Astrazeneca vaccine.

Open days for vaccination

Canepa had been vaccinated on May 25, during one of the open days organized throughout Italy, during which citizens of legal age who still do not have a reservation, can voluntarily undergo the immunization procedure. In Turin alone, on June 2, the 6,000 seats available for the following weekend were reserved in a matter of minutes.

Among the youngest, these events have been very successful: the news in recent days speak of hundreds of minors, often accompanied by their parents, sometimes queuing for hours at the vaccination centers to be able to each have their own dose. .

Although the risk of COVID is infinitely lower in terms of hospitalization and death. Many teens have chosen to voluntarily undergo the vaccine. Canepa’s friends singled out Corriere della Sera: “I was preparing for my high school exams and I was thinking of spending a summer off.”

The second dose, better from another vaccine

The Scientific-Technical Committee (CTC) has committed itself in these hours to formulate a new evaluation of the Anglo-Swedish vaccine, after the one two months ago that recommended administration only to those over 60 years of age – it now seems willing to review the lines of use.

The shared guidance appears to be a new “recommendation”, this time stricter, for AstraZeneca management only to those who have reached at least 60 years: in essence, it removes the word “preferably” which allowed wide discretion to regional authorities .

It remains to be resolved, in that case, what happens to the first doses that have already been administered. In this regard, the solution would be to inoculate a dose from another company. “This is due – explained one of the Committee’s scientists to the press – because the most recent studies say that with the second dose of another, an antibody response is obtained even more effective than that which is repeated with the same company” .

Controversy over the recommendations

And to untangle, however, there is also the knot of responsibility. The governor of Liguria, Toti, blames them entirely on the “highest technical and scientific bodies”, even the Government points a finger in the same direction.

According to the executive, the excessively vague formula with which the vaccine was recommended “preferably” to those over 60 years of age, would have left too much discretion to the regions and local authorities, which in these times have ended up administering it even when the cost-effectiveness ratio. benefit would have suggested greater caution.

At the end of April, a study by the European Medicines Agency had put in writing how, among young people, the risks associated with inoculation with AstraZeneca outweighed the possible benefits. In fact, among those under 30 years of age, compared to a death rate from Coronavirus close to zero, the number of thrombotic events after recruitment was – with 1.9 cases per 100,000 patients – much higher than in the age groups later.

Precisely young women, like Camilla Canepa, were the most affected by thrombotic events after the vaccine, according to statistical data collected by the EMA.